Nakamoto Inc. NAKA
Medical/Nursing Services · IPO 2024 · data as of November 13, 2026
Nakamoto Inc. (NAKA) is a healthcare company listed in the US with a market value of about $92M. In the twelve months to September 30, 2026 it had revenue of $43M and net income of -$249M, a net margin of -581.0%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.2, a 5-year average ROIC of -114%.
About Nakamoto
Nakamoto is listed in the US and classified in medical/nursing services, IPO year 2024. It was profitable in 0 of the last 3 years in our data.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $43M | $2M | $3M | $4M |
| Net income | -$249M | -$52M | -$4M | -$2M |
| Free cash flow | — | -$24M | -$3M | -$463909 |
| EPS (diluted) | $46.33 | $-0.26 | $-0.67 | $-0.36 |
| Net margin | -581.0% | -2867.7% | -133.0% | -42.9% |
| ROIC | — | -21.5% | -78.9% | -242.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $13.33, 167% above the current price; targets range from $10.00 to $17.00; the consensus rating is “none”; expected EPS is $-21.06 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Nakamoto’s P/E ratio?
About 0.2, based on the last twelve months of diluted earnings per share.
Does Nakamoto pay a dividend?
Not currently.
Is Nakamoto a good stock to buy?
We do not give buy or sell advice. Nakamoto scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.